TheCalreticulingene and myeloproliferative neoplasms

Mutant calreticulin: when a chaperone becomes intrusive

(2016) M. Cazzola   BLOOD

Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms

(2016) M. Araki et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants

(2015) I. Chachoua et al.   BLOOD

Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis

(2015) C. Marty et al.   BLOOD

CALR mutations screening in wild type JAK2V617F and MPLW515K/L Brazilian myeloproliferative neoplasm patients

(2015) Daniela Prudente Teixeira Nunes et al.   BLOOD CELLS MOLECULES AND DISEASES

Molecular diagnostics of myeloproliferative neoplasms

(2015) Stephen E. Langabeer et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms

(2015) Qiu-Mei Yao et al.   Hematology

Calreticulin gene mutations in the myeloproliferative neoplasms: Dameshek's other “myelostimulatory” factor

(2015) Brady L. Stein et al.   LEUKEMIA & LYMPHOMA

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis

(2015) P Guglielmelli et al.   Blood Cancer Journal

CALRmutations in myeloproliferative neoplasms: Hidden behind the reticulum

(2014) Paola Guglielmelli et al.   AMERICAN JOURNAL OF HEMATOLOGY

Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients

(2014) Ayalew Tefferi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

(2014) E. Rumi et al.   BLOOD

The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants

(2014) A. Tefferi et al.   BLOOD

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis

(2014) E. Rumi et al.   BLOOD

Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms

(2014) Paola Guglielmelli et al.   Expert Review of Hematology

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

(2013) G. Rotunno et al.   BLOOD

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

(2013) E. Rumi et al.   BLOOD

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Calreticulin: non-endoplasmic reticulum functions in physiology and disease

(2009) Leslie I. Gold et al.   FASEB JOURNAL

Transcriptional control of the calreticulin gene in health and disease

(2008) Yuanyuan Qiu et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis

(2008) Juergen Thiele et al.   Current Hematologic Malignancy Reports